How much does each box of Seladelpar cost? Is it stressful for patients?

Seladelpar (Seladelpar), as an innovative PPAR-delta agonist, is mainly used to treat patients with primary biliary cholangitis (PBC), especially those who have poor response or intolerance to traditional treatment drugs such as ursodeoxycholic acid (UDCA). This drug received accelerated approval from the US FDA in 2024, marking a new stage in the treatment of PBC. Although its efficacy has attracted much attention, Siladepa has not yet been officially launched in China, and patients can only obtain the drug through overseas channels, which has brought inconvenience and additional financial burden to many patients.

In overseas markets, the price of Siladepa is relatively high. Taking the United States as an example, the monthly cost of the drug is approximately 1.26 US dollars, equivalent to about 90,000 yuan. This price reflects the cost of new drug research and development, patent protection, and pricing strategies in the medical market, but it is undoubtedly a heavy financial burden for most patients. In particular, chronic diseases require long-term medication. The continued high expenses put many patients and families under great pressure, affecting the widespread use of drugs and patients' treatment compliance.

Currently, there are no formal sales channels for Siladepa in the Chinese market, and patients can only purchase it through overseas medical channels, which in turn involves additional costs for imported drugs, including transportation, tariffs, etc., which further aggravates the financial burden on patients. More importantly, the drug is not included in the medical insurance system, which means that patients need to pay for it in full out of pocket. For most patients, financial status becomes an important consideration in whether they can receive this advanced treatment, so doctors and patients need to weigh carefully when formulating treatment plans.

Overall, Siladepa, as a new targeted drug for primary biliary cholangitis, has good treatment prospects. However, its high price and lack of domestic medical insurance support have put patients under greater financial pressure. Faced with this reality, patients not only need to pay attention to the efficacy and safety of drugs, but also need to actively seek professional advice from doctors and rationally plan treatment plans based on their own economic conditions. In the future, as the drug gradually enters the market in more countries and may be included in medical insurance, the burden on patients is expected to be alleviated.

Reference materials:https://www.drugs.com/seladelpar.html